Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (16)

2024

  1. Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer

    Actas Urologicas Espanolas

  2. Why is it necessary to produce a BCG strain in Spain?

    Actas Urologicas Espanolas

2023

  1. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer

    Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126

  2. Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply

    Actas Urologicas Espanolas

  3. Hormone sensitive protocol for metastatic prostate cancer, an update

    Actas Urologicas Espanolas, Vol. 47, Núm. 4, pp. 244-249

2022

  1. Non-metastatic castration-resistant prostate cancer: management recommendations

    Actas Urologicas Espanolas, Vol. 46, Núm. 4, pp. 193-213

2018

  1. Actualización del papel de la quimioterapia endovesical en el cáncer de vejiga no músculo-invasivo

    Actas Urologicas Espanolas

  2. Radio-223 en la secuencia terapéutica del cáncer de próstata resistente a la castración metastásico

    Actas Urologicas Espanolas

  3. Review of evidence on handling hazardous drugs and Products in Urology Services; Consensus document between the Spanish Urology Association and the Spanish Society of Health-System Pharmacists

    Biomedical Instrumentation and Technology, Vol. 42, Núm. 5, pp. 212-215

  4. Review of the evidence on handling drugs and hazardous products in Urology Departments. Consensus document between the Spanish Urological Association and the Spanish Society of Hospital Pharmacy

    Actas Urologicas Espanolas, Vol. 42, Núm. 6, pp. 375-380

  5. Safety and efficacy of various strains of bacille Calmette-Guérin in the treatment of bladder tumours in standard clinical practice

    Actas Urologicas Espanolas, Vol. 42, Núm. 4, pp. 238-248

2017

  1. Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study – GESCAP group

    Actas Urologicas Espanolas, Vol. 41, Núm. 6, pp. 359-367

2016

  1. Tendencias de tratamiento en el cáncer de próstata clínicamente localizado. Análisis poblacional a nivel nacional: grupo GESCAP

    Actas Urologicas Espanolas, Vol. 40, Núm. 4, pp. 209-216

2013

  1. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study

    British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130

  2. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

    British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572

2011

  1. Prostate cancer in Spain: From guidelines to clinical practice

    BJU International, Vol. 108, Núm. 1, pp. 61-66